NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)

with

INDEPENDENT AUDITOR'S REVIEW REPORT

For the three-month and the nine-month period ended 30 September 2026

NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (UNAUDITED)
For the three-month and the nine-month period ended 30 September 2026

Table of contents **Page**

Independent Auditor's Review Report	-
Condensed consolidated Statement of Financial Position	1
Condensed consolidated Statement of Profit or Loss and Other Comprehensive Income	2
Condensed consolidated Statement of Changes in Equity	3
Condensed consolidated Statement of Cash Flows	4-5
Notes to the Condensed consolidated interim Financial Statements	6-24

KPMG Professional Services Company
Zahran Business Center
Prince Sultan Street
P. O. Box 55078
Jeddah 21534
Kingdom of Saudi Arabia
Commercial Registration No 4030290792

Headquarters in Riyadh

شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية
مركز زهران للأعمال
شارع الأمير سلطان
ص. ب. ٥٥٠٧٨
جده ٢١٥٣٤
المملكة العربية السعودية
سجل تجاري رقم ٤٠٣٠٢٩٠٧٩٢

المركز الرئيسي في الرياض

Independent Auditor's Report on review of condensed consolidated interim financial statements

To the Shareholders of Nahdi Medical Company (a Saudi Joint Stock Company)

Introduction

We have reviewed the accompanying 30 September 2026 condensed consolidated interim financial statements of Nahdi Medical Company (the "Company") and its subsidiaries ("the Group"), which comprises:

- the condensed consolidated statement of financial position as at 30 September 2026;
- the condensed consolidated statement of profit or loss and other comprehensive income for the three-month and the nine-month period ended 30 September 2026;
- the condensed consolidated statement of changes in equity for the nine-month period ended 30 September 2026;
- the condensed consolidated statement of cash flows for the nine-month period ended 30 September 2026; and
- the notes to the condensed consolidated interim financial statements.

Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

Scope of Review

We conducted our review in accordance with the International Standard on Review Engagements 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' that is endorsed in the Kingdom of Saudi Arabia. A review of condensed consolidated interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

© 2026 KPMG Professional Services Company, a professional closed joint stock company registered in the Kingdom of Saudi Arabia with a paid-up capital of SAR110,000,000 and a non-partner member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee.
All rights reserved.

٢٠٢٦ © شركة كي بي إم جي للاستشارات المهنية مساهمة مهنية، شركة مساهمة مهنية مقفلة مسجلة في المملكة العربية السعودية، رأس مالها (١١٠،٠٠٠،٠٠٠) ريال سعودي مدفوع بالكامل، وهي عضو غير شريك في الشبكة العالمية لشركات كي بي إم جي المستقلة والتابعة لـ كي بي إم جي العالمية المحدودة، شركة انجليزية خاصة محدودة بالضمان. جميع الحقوق محفوظة.

Independent Auditor's Report on review of condensed consolidated interim financial statements (CONTINUED)

To the Shareholders of Nahdi Medical Company (a Saudi Joint Stock Company)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying 30 September 2026 condensed consolidated interim financial statements of Nahdi Medical Company and its subsidiaries are not prepared, in all material respects, in accordance with IAS 34, 'Interim Financial Reporting' that is endorsed in the Kingdom of Saudi Arabia.

KPMG Professional Services Company

Ebrahim Oboud Baeshen

Regional Managing Partner - Jeddah
License No. 382

Jeddah, 28 October 2026
Corresponding to 17 Jumada Al Awal 1448H

NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (UNAUDITED)
As at 30 September 2026
(Expressed in Saudi Riyals unless otherwise stated)

	Notes	30 September 2026 (Unaudited)	31 December 2025 (Audited)
		﷼	﷼
ASSETS			
Property and equipment	4	**1,175,504,860**	1,202,956,432
Intangible assets		**66,138,244**	67,615,618
Investment properties	5	**255,900,823**	255,900,823
Right-of-use assets	6	**1,800,096,639**	1,825,289,731
Investment in Sukuk	7	**200,000,000**	--
Net investment from finance lease	8	**15,283,410**	10,627,015
Prepayments and other non-current assets		**27,638,876**	29,465,214
Non-current assets		**3,540,562,852**	3,391,854,833
Inventories	9	**2,141,601,075**	2,277,875,619
Trade receivables	10	**439,244,416**	261,431,783
Prepayments and other current assets		**252,819,301**	203,816,766
Net investment from finance lease - current portion	8	**2,148,417**	1,460,016
Financial assets measured at FVTPL	11	**354,205,335**	--
Cash and cash equivalents	12	**159,075,477**	554,443,212
Current assets		**3,349,094,021**	3,299,027,396
Total assets		**6,889,656,873**	6,690,882,229
EQUITY AND LIABILITIES			
Equity			
Share capital	13-A	**1,300,000,000**	1,300,000,000
Foreign currency translation reserve		**245,054**	111,799
Retained earnings		**1,395,553,408**	1,443,426,566
Total shareholders' equity		**2,695,798,462**	2,743,538,365
Liabilities			
Lease liabilities	6	**1,352,176,613**	1,363,088,843
Accruals and other non-current liabilities		**10,675,434**	15,237,863
Employee benefit liabilities	14	**391,733,358**	421,460,663
Non-current liabilities		**1,754,585,405**	1,799,787,369
Trade payables		**1,605,539,943**	1,418,612,325
Lease liabilities – current portion	6	**439,906,685**	420,242,217
Accruals and other current liabilities		**361,663,635**	257,987,135
Zakat and tax provision	15	**32,162,743**	50,714,818
Current liabilities		**2,439,273,006**	2,147,556,495
Total liabilities		**4,193,858,411**	3,947,343,864
Total equity and liabilities		**6,889,656,873**	6,690,882,229

Approved by:

Abdullah Al Nahdi	Yasser Joharji	Mohammed Al-Khubani
Chairman	CEO	CFO

The attached notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (UNAUDITED)
For the nine-month period ended 30 September 2026
(Expressed in Saudi Riyals unless otherwise stated)

	Notes	Three-month period ended 30 September		Nine-month period ended 30 September	
		2026	2025	**2026**	2025
		﷼	﷼	﷼	﷼
Revenue	16	**2,691,958,869**	2,461,456,895	**8,160,657,527**	7,623,975,278
Cost of revenue		**(1,735,025,084)**	(1,520,887,581)	**(5,208,359,592)**	(4,773,629,348)
Gross profit		**956,933,785**	940,569,314	**2,952,297,935**	2,850,345,930
Other operating income		**4,046,500**	3,614,181	**14,883,512**	23,126,920
Selling and distribution expenses		**(667,831,901)**	(650,322,230)	**(1,969,733,082)**	(1,872,801,637)
General and administrative expenses		**(97,289,781)**	(106,289,973)	**(295,984,464)**	(282,468,701)
Operating profit for the period		**195,858,603**	187,571,292	**701,463,901**	718,202,512
Finance costs		**(36,812,924)**	(37,393,746)	**(108,512,038)**	(110,567,907)
Finance income		**4,925,682**	16,280,175	**27,082,250**	49,873,494
Unrealized gain on financial assets measured at FVTPL	11	**7,391,586**	--	**12,522,336**	--
Other income		**266,964**	63	**821,504**	9,735
Profit for the period before zakat and tax		**171,629,911**	166,457,784	**633,377,953**	657,517,834
Zakat and tax (charge) / reversal	15	**143,081**	(5,208,928)	**(10,695,995)**	(2,701,917)
Net profit for the period		**171,772,992**	161,248,856	**622,681,958**	654,815,917
Other comprehensive income					
Items that will not be reclassified to profit or loss in subsequent periods					
Re-measurement gain on defined benefit plans	14	**12,281,387**	4,383,923	**57,444,884**	2,943,076
Items that may be reclassified to profit or loss in subsequent periods					
Exchange differences on translation of foreign operations		**47,480**	(133,512)	**133,255**	166,752
Other comprehensive income for the period		**12,328,867**	4,250,411	**57,578,139**	3,109,828
Total comprehensive income for the period		**184,101,859**	165,499,267	**680,260,097**	657,925,745
Earnings per share (﷼)					
Basic and diluted, earnings per share attributable to ordinary equity holders of the Parent Company	17	**1.32**	1.24	**4.79**	5.04

Approved by:

Abdullah Al Nahdi	Yasser Joharji	Mohammed Al-Khubani
Chairman	CEO	CFO

The attached notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
For the nine-month period ended 30 September 2026
(Expressed in Saudi Riyals unless otherwise stated)

	Share capital	Statutory reserve	Retained earnings	Foreign currency translation reserve	Total
	﷼	﷼	﷼	﷼	﷼
Balance as at 1 January 2025 (audited)	1,300,000,000	369,207,440	916,969,664	(74,256)	2,586,102,848
Net profit for the period	--	--	654,815,917	--	654,815,917
Other comprehensive income for the period	--	--	2,943,076	166,752	3,109,828
Total comprehensive income for the period	--	--	657,758,993	166,752	657,925,745
Dividends (note 13-B)	--	--	(728,000,000)	--	(728,000,000)
Transfer of statutory reserve to retained earnings (note 13-C)	--	(369,207,440)	369,207,440	--	--
Balance as at 30 September 2025 (unaudited)	1,300,000,000	--	1,215,936,097	92,496	2,516,028,593
Balance as at 1 January 2026 (audited)	1,300,000,000	--	1,443,426,566	111,799	2,743,538,365
Net profit for the period	--	--	622,681,958	--	622,681,958
Other comprehensive income for the period	--	--	57,444,884	133,255	57,578,139
Total comprehensive income for the period	--	--	680,126,842	133,255	680,260,097
Dividends (note 13-B)	--	--	(728,000,000)	--	(728,000,000)
Balance as at 30 September 2026 (unaudited)	**1,300,000,000**	--	**1,395,553,408**	**245,054**	**2,695,798,462**

Approved by:

Abdullah Al Nahdi	Yasser Jomarji	Mohammed Al-Khubani
Chairman	CEO	CFO

The attached notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

NAHDI MEDICAL COMPANY
(A Saudi Joint Stock Company)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
For the nine-month period ended 30 September 2026
(Expressed in Saudi Riyals unless otherwise stated)

	Notes	Nine-month period ended 30 September 2026 ﷼	2025 ﷼
Operating activities			
Profit for the period before zakat		**633,377,953**	657,517,834
Adjustment to reconcile profit for the period before zakat to net cash flows from operating activities:			
Depreciation of property and equipment	4	**223,384,463**	214,320,545
Depreciation of right-of-use assets	6	**363,051,380**	350,345,203
Amortisation of intangible assets		**24,343,606**	23,542,129
Gain on disposal of property and equipment		**(447,977)**	(74,665)
(Gain) / Loss on termination of leases		**(2,165,555)**	1,428,166
Unrealized gain on financial assets measured at FVTPL		**(12,522,336)**	--
Creation for Impairment losses on trade receivables	10	**1,664,827**	2,535,956
Creation of provision for inventories	9	**31,979,625**	30,946,769
Provision for employee benefits	14	**52,383,949**	58,201,251
Finance costs		**108,512,038**	110,567,907
Finance income		**(27,082,250)**	(49,873,494)
		1,396,479,723	1,399,457,601
Working capital adjustments:			
Inventories		**104,294,919**	(528,302,212)
Trade receivables		**(179,477,460)**	(119,874,908)
Prepayments and other current assets		**(45,507,866)**	28,027,431
Trade and other payables		**186,927,618**	501,074,662
Accruals and other current liabilities		**101,680,117**	(105,348,128)
Cash from operations		**1,564,397,051**	1,175,034,446
Finance costs paid		**(108,512,038)**	(110,567,907)
Zakat paid	15	**(32,397,369)**	(41,270,994)
Zakat refund	15	**3,149,299**	--
Employee benefits paid	14	**(24,664,063)**	(16,862,982)
Net cash flows from operating activities		**1,401,972,880**	1,006,332,563
Investing activities			
Purchase of property and equipment	4	**(198,502,660)**	(295,462,915)
Proceeds from disposal of property and equipment		**227,086**	75,338
Investment in Sukuk	7	**(200,000,000)**	--
Investment in financial assets measured at FVTPL		**(342,230,980)**	--
Purchase of intangible assets		**(22,867,812)**	(22,877,968)
Proceeds from investment fund redemption		**547,981**	--
Finance income received		**24,968,022**	48,965,033
Principal received from finance lease		**1,900,000**	1,700,000
Net cash flows used in investing activities		**(735,958,363)**	(267,600,512)
Financing activities			
Payment of principal portion of lease liabilities		**(333,515,507)**	(331,026,261)
Dividend paid	13-B	**(728,000,000)**	(728,000,000)
Cash flows used in financing activities		**(1,061,515,507)**	(1,059,026,261)
Decrease in cash and cash equivalents		**(395,500,990)**	(320,294,210)
Cash and cash equivalents at the beginning of the period		**554,443,212**	956,809,579
Net foreign exchange difference		**133,255**	166,752
Cash and cash equivalents at the end of the period	12	**159,075,477**	636,682,121

The attached notes from 1 to 23 form an integral part of these condensed consolidated interim financial statements.

	Notes	Nine-month period ended 30 September 2026 ﷼	2025 ﷼
Supplementary non-cash information			
Transfer of statutory reserve to retained earnings		**--**	369,207,440
Additions to net investment in finance lease	8	**6,575,012**	13,673,738
Additions to right-of-use assets	6	**362,211,148**	618,122,877
Finance income receivable		**1,444,444**	--

Approved by:

Abdullah Al Nahdi	Yasser Joharji	Mohammed Al-Khubani
Chairman	CEO	CFO

1. CORPORATE INFORMATION

Nahdi Medical Company (the "Parent Company" or the "Company") is a Saudi Joint Stock Company formed under Companies Law in the Kingdom of Saudi Arabia under Commercial Registration No. 4030053868 dated 1 October 2003 (corresponding to 5 Sha'ban 1424H) and Unified No. 7018056114. The Group is operating in accordance with the Ministry of Health License No. 26-101-31-67-3 dated 28 December 2003 (corresponding to 22 Dhul-Hijjah 1424H).

The principal activity of the Group is the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods and medical equipment.

The Group operates mainly in the Kingdom of Saudi Arabia ("KSA") and the United Arab Emirates ("UAE") and its Head Office is located at the following address:

Nahdi Medical Company,
PO. Box 17129, King Abdulaziz Road, Murjan District,
Jeddah 23715, Kingdom of Saudi Arabia.

2. BASIS OF PREPARATION

2.1 Statement of compliance

These condensed consolidated interim financial statements for the three-month and the nine-month period ended 30 September 2026 have been prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia ("KSA"). The Group has prepared the condensed consolidated interim financial statements on the basis that it will continue to operate as a going concern. The management considers that there are no material uncertainties that may cast significant doubt over this assumption. The management have formed a judgment that there is a reasonable expectation that the Group has adequate resources to continue in business for the foreseeable future, and not less than 12 months from the end of the reporting period.

These condensed consolidated interim financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025. In addition, results for the condensed consolidated interim financial statements for the period ended 30 September 2026 are not necessarily indicative of the results that may be expected for the financial year ending 31 December 2026.

2.2 Basis of measurement

These condensed consolidated interim financial statements have been prepared under the historical cost basis except the employee retirement benefit is recognised at the present value of future obligations using the Projected Unit Credit Method.

The Group has prepared the condensed consolidated financial statements on the basis that it will continue to operate as a going concern.

2.3 Functional and presentation currency

These condensed consolidated interim financial statements are presented in Saudi Riyals ("﷼") which is also the functional currency of the Group.

2. BASIS OF PREPARATION (continued)

2.4 Basis of consolidation

These condensed consolidated interim financial statements include the financial information of the Parent Company and the following direct and indirect subsidiaries (collectively referred to "the Group"), in which the Group exercises control as at 30 September 2026.

Subsidiary name	Legal structure	Country of incorporation	Principal business activity	Effective ownership interest	
				30 September 2026	31 December 2025
Al Nahdi Care	Limited liability company	KSA	Clinics	**100%**	100%
Sakhaa Golden Company**	Limited liability company	KSA	Labor Services	**100%**	100%
Nahdi Investment Company***	Limited liability company	UAE	Holding Company	**100%**	100%
Rawa Alsihha Company*	Limited liability company	KSA	Services	**100%**	--

* During the period ended 30 September 2026, the Company established Rawa Alsihha Company as a Limited Liability Company registered in the Kingdom of Saudi Arabia under the Commercial Registration no. 7018056114 dated 2 Safar 1448H (corresponding to 16 July 2026) issued in Jeddah. The subsidiary has been established to support the Company's strategic objectives and future growth plans by enhancing its capabilities across supply chain, logistics, distribution, and delivery solutions. The share capital of the subsidiary was set at ﷼100,000, divided into 100 cash shares with a value of ﷼1,000 per share. The Company's first financial year commenced on the date of its registration in the Commercial Register and ends on 31 December 2027. Thereafter, each financial year shall comprise twelve months ending on 31 December.

** As at 30 September 2026, Al Sakhaa Golden Trading and Contracting Company has an investment in the following subsidiary:

Subsidiary name	Legal structure	Country of incorporation	Principal business activity	Effective ownership interest	
				30 September 2026	31 December 2025
Al Sakhaa Integrated Solutions	Limited liability company	Egypt	IT consulting	**99%**	99%

The remaining 1% is held by Nahdi Investment Company, who holds the share for the beneficial interest of the company and accordingly there is no non-controlling interest.

2. BASIS OF PREPARATION (continued)

2.4 Basis of consolidation (continued)

***As at 30 September 2026, Nahdi Investment Company also has investments in the following subsidiaries:

Subsidiary name	Legal structure	Country of incorporation	Principal business activity	Effective ownership interest	
				30 September 2026	31 December 2025
Nahdi Drug Store	Limited liability company	UAE	Drug store	**99%**	99%
Al Nahdi Pharmacy	Limited liability company	UAE	Pharmacy	**99%**	99%

The remaining 1% is held by Mr. Saleh Mohamed Amer Salmeen Al Hajeri of Al Nahdi Investment Co. who holds the share for the beneficial interest of the company.

The financial statements of the subsidiaries are prepared for the same reporting period as that of the Group, using consistent accounting policies of the Group.

Transactions eliminated on consolidation
Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated.

Unrealized losses (if any) are eliminated in the same way as unrealized gains, but only to the extent that there is no evidence of impairment.

Generally, there is a presumption that a majority of voting rights results in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has control over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee.
- Rights arising from other contractual arrangements.
- The Group's voting rights and potential voting rights.

The Group re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control. Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary.

2. BASIS OF PREPARATION (continued)

2.4 Basis of consolidation (continued)

Control is achieved when the Group is exposed, or has rights, to variable returns from its transactions with the investee and has the ability to affect those returns through exercising its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e., existing rights that give the Group the current ability to direct the relevant activities of the investee).
- Exposure, or rights, to variable returns from its transactions with the investee.
- The ability to use its power over the investee to affect its returns.

2.5 Significant accounting judgments, estimates and assumptions

The preparation of the Group's condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. The significant judgments made by management in applying the Group's accounting policies and the methods of computation and the key sources of estimation are the same as those that applied to the consolidated financial statements for the year ended 31 December 2025.

3. NEW STANDARDS, AMENDMENTS TO STANDARDS AND INTERPRETATIONS

3.1 New Standards, Amendment to Standards and Interpretations

The new standards and amendments to standards disclosed in the Group's annual consolidated financial statements remain unchanged.

IFRS 18 *Presentation and Disclosure in Financial Statements* will replace IAS 1 *Presentation of Financial Statements* and applies for annual reporting periods beginning on or after 1 January 2027. The Group has not early adopted the new accounting standard in preparing these interim financial statements; however, earlier application is permitted.

The Group is in the process of assessing the estimated impact that the initial application of IFRS 18 will have on its consolidated financial statements.

A. Structure of the statement of profit or loss

IFRS 18 requires entities to classify all income and expenses into five categories in the statement of profit or loss – namely operating, investing, financing, income tax and discontinued operations. Classification of income and expenses depends on the main business activities of an entity. Based on preliminary assessment, the Group has determined that it does not have a specified main business activity of investing in assets and/or providing financing to customers.

3. NEW STANDARDS, AMENDMENTS TO STANDARDS AND INTERPRETATIONS (continued)

3.1 New Standards, Amendment to Standards and Interpretations (continued)

A. Structure of the statement of profit or loss (continued)

Neither net profit nor net assets will change as a result of the Group's adoption of IFRS 18. However, the Group will be required to present two newly defined subtotals, which are 'operating profit' and 'profit or loss before financing and income taxes'. The operating profit subtotal differs from the current operating profit subtotal presented by the Group. Based on the Group's preliminary assessment, the Group expects below changes to the current structure of the statement of profit or loss:

1. Investing category

Interest income and expenses are generally included in finance income and finance costs under the Group's current accounting policy. IFRS 18 provides specific guidance on the income and expenses classified in the investing and financing categories.

Finance income on certain financial assets held by the Group (e.g. income from Islamic Murabaha deposits, financial assets measured at FVTPL and finance income from finance lease) will be classified and presented in the investing category.

2. Financing category

The interest cost component of the Employee Retirement Benefit obligations will move to the financing category whereas Interest Expense on Lease Liabilities will continue to be classified in the financing category.

3. Operating category

The operating category remains the residual category for all other items.

4. Foreign exchange

Foreign exchange gains are currently included and presented in finance income. Under IFRS 18, foreign exchange differences are required to be presented in the same category as the income and expenses from the items that gave rise to the differences. For example, foreign exchange differences on trade payables will be classified in the operating category.

B. Management-defined performance measures

Management-defined performance measures (MPMs) are subtotals of income and expenses used in public communications outside the financial statements that communicate to users management's view of an aspect of the financial performance of the entity as a whole. The Group will be required to disclose specific information about MPMs in a single note in the financial statements.

3. NEW STANDARDS, AMENDMENTS TO STANDARDS AND INTERPRETATIONS (continued)

3.1 New Standards, Amendment to Standards and Interpretations (continued)

B. Management-defined performance measures (continued)

The Group has developed a process to determine public communications relevant when identifying MPMs. MPMs relate to the same reporting period as the financial statements. Therefore, MPMs disclosed by the Group following adoption of IFRS 18 will be determined based on public communications issued by the Group relating to the 2027 interim reporting period.

C. Principles of aggregation and disaggregation

IFRS 18 provides enhanced principles on how to group information in the financial statements (i.e. the primary financial statements and the notes). It also introduces guidance on labelling and describing items presented in the primary financial statements or disclosed in the notes.

The Group is assessing the grouping of items on the basis of similar and dissimilar characteristics. Based on this assessment, it will present line items in the primary financial statements that provide useful structured summaries and disclose additional material information in the notes.

The Group is also assessing line items currently labelled as ‘other’ and will use more informative labels.

D. Consequential amendments

IFRS 18 introduces consequential amendments to IAS 7, which require entities to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method. The Group currently uses ‘profit or loss’ as the starting point of the reconciliation to cash flows from operating activities. Certain adjusting items included in the reconciliation will change as a result of the new starting point.

The consequential amendments also provide specific guidance on the classification of interest and dividend cash flows. The Group will classify cash flows from interest paid as financing activities rather than operating activities under this guidance. Cash flows from interest and dividends received and from dividends paid will continue to be classified as investing activities and financing activities, respectively.

4. PROPERTY AND EQUIPMENT

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Cost:			
At the beginning of the period / year	**2,819,495,194**	2,474,844,516	2,474,844,516
Additions during the period / year	**198,502,660**	295,462,915	387,085,742
Disposals during the period / year	**(7,181,422)**	(339,427)	(517,456)
Write-offs during the period / year	**(23,220,345)**	(33,085,000)	(41,917,608)
At the end of the period / year	**2,987,596,087**	2,736,883,004	2,819,495,194
Depreciation:			
At the beginning of the period / year	**1,616,538,762**	1,362,256,729	1,362,256,729
Depreciation charge for the period / year	**223,384,463**	214,320,545	289,246,261
Disposals during the period / year	**(7,178,426)**	(338,754)	(516,769)
Write-offs during the period / year	**(20,653,572)**	(27,753,919)	(34,447,459)
At the end of the period / year	**1,812,091,227**	1,548,484,601	1,616,538,762
Net book value:			
At the end of the period / year	**1,175,504,860**	1,188,398,403	1,202,956,432

5. INVESTMENT PROPERTIES

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Cost:			
At the beginning and end of the period / year	**262,963,234**	262,963,234	262,963,234
Accumulated Impairment loss:			
At beginning of the period / year	**7,062,411**	7,062,411	7,062,411
Reversal of impairment loss for the period/ year	**--**	--	--
At the end of the period / year	**7,062,411**	7,062,411	7,062,411
Net book value:			
At the end of the period / year	**255,900,823**	255,900,823	255,900,823

The Group's investment properties mainly represent the parcels of land in KSA which are currently held for undetermined future use. The fair value of the Group's investment properties as at 30 November 2025 was valued at ﷼348.4 million (30 November 2024: ﷼346.9 million).

5. INVESTMENT PROPERTIES (continued)

The fair value of the Group's investment properties, as at 30 November 2025 was determined on the basis of the valuation exercise carried out by two independent external real estate valuers Abdullah Al Kathiri Real Estate Evaluation Office and Abdulaziz Al-Azab Real Estate Evaluation Co. (2024: Abdullah Al Kathiri Real Estate Evaluation Office and Abdulaziz Al-Azab Real Estate Evaluation Co.) accredited by the Saudi Authority for Accredited Valuers ("TAQEEM"). Both valuers have appropriate qualifications and relevant experience in the fair value measurement of properties in the relevant locations. Management adopted the lower of the two valuation results as the basis for measuring the fair value of the investment properties. Management believes that the fair value mentioned is not significantly different from their current market value.

The fair value of the lands has been determined based on income method, a valuation model in accordance with that recommended by the Saudi Authority for Accredited Valuers was applied.

This valuation model is in accordance with those recommended by the International Valuation Standards Committee and is consistent with the principles in IFRS 13.

All investment properties of the Group are currently held for undetermined future use.

The Group has no restrictions on the realizability of its investment properties and no contractual obligations to purchase, construct or develop investment properties or for repair, maintenance, and enhancement.

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

Set out below, are the carrying amounts of the Group's right-of-use assets and lease liabilities and the movements during the period / year:

	30 September 2026		30 September 2025		31 December 2025	
	Right-of-use assets (Unaudited)	**Lease Liabilities (Unaudited)**	Right-of-use assets (Unaudited)	Lease Liabilities (Unaudited)	Right-of-use assets (Audited)	Lease liabilities (Audited)
	﷼	**﷼**	﷼	﷼	﷼	﷼
At the beginning of the period / year	**1,825,289,731**	**1,783,331,060**	1,607,005,320	1,529,755,774	1,607,005,320	1,529,755,774
Addition during the period / year	**362,211,148**	**368,786,160**	618,122,877	631,855,925	756,615,702	770,193,330
Modifications during the period / year*	**(10,203,856)**	**(10,203,856)**	(13,917,368)	(13,917,368)	(8,758,582)	(8,758,582)
Termination during the period / year**	**(14,149,004)**	**(16,314,559)**	(20,014,237)	(18,586,071)	(55,646,679)	(53,903,538)
Depreciation during the period / year	**(363,051,380)**	**--**	(350,345,203)	--	(473,926,030)	--
Accretion of interest during the period / year	**--**	**66,572,229**	--	70,117,378	--	88,014,420
Payments during the period / year	**--**	**(400,087,736)**	--	(401,143,639)	--	(541,970,344)
At the end of the period / year	**1,800,096,639**	**1,792,083,298**	1,840,851,389	1,798,081,999	1,825,289,731	1,783,331,060

* The lease modifications during the period relates to a reduction of lease payments for 37 pharmacies (year ended 31 December 2025: 63 pharmacies) lease contracts which resulted in decrease in the carrying value of lease liabilities and right of use asset.

** The lease terminations during the period relates to 17 pharmacies (year ended 31 December 2025: 49 pharmacies) lease contracts terminated before the expiry date which results to lease termination gain amounting to ﷼ 2,165,555 (year ended 31 December 2025 loss: ﷼1,743,141) in the condensed consolidated statement of profit or loss.

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (continued)

The following are the lease liabilities as classified in the condensed consolidated interim statement of financial position:

	30 September 2026 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Current	**439,906,685**	420,242,217
Non-current	**1,352,176,613**	1,363,088,843
	1,792,083,298	1,783,331,060

The additions, terminations and modifications during the period/ year happened in normal course of business.

7. INVESTMENT IN SUKUK

On 6 May 2026, the Group purchased an investment in "Additional Tier 1 Capital Sukuk" of Alinma Bank amounting to ﷼200,000,000, with a profit rate of 6.5%. The Sukuk is a perpetual instrument with the first call date after five years and is measured as an equity investment at fair value through other comprehensive income.

During the period ended 30 September 2026, the Group recognised finance income from the investment in Sukuk amounting to ﷼4.69 million, as presented in the condensed consolidated statement of profit or loss. As at 30 September 2026, there was no change in the fair value of the investment.

8. NET INVESTMENT FROM FINANCE LEASE

	30 September 2026 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
As at 1 January	**12,087,031**	--
Addition	**6,575,012**	13,673,738
Sublease Interest income	**669,784**	1,090,745
Payments during the period / year	**(1,900,000)**	(2,677,452)
At the end of the period / year	**17,431,827**	12,087,031
Current	**2,148,417**	1,460,016
Non-current	**15,283,410**	10,627,015

9. INVENTORIES

	30 September 2026 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Inventories	**2,262,397,056**	2,393,353,182
Less: Impairment of inventories	**(120,795,981)**	(115,477,563)
	2,141,601,075	2,277,875,619

Movement in the impairment of inventories was as follows:

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
At the beginning of the period / year	**115,477,563**	106,562,953	106,562,953
Charge for the period / year	**31,979,625**	30,946,769	61,292,048
Written off during the period / year	**(26,661,207)**	(27,808,382)	(52,377,438)
At the end of the period / year	**120,795,981**	109,701,340	115,477,563

10. TRADE RECEIVABLES

	30 September 2026 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Trade receivables	**446,868,861**	267,407,699
Less: Impairment losses on trade receivables	**(7,624,445)**	(5,975,916)
	439,244,416	261,431,783

Movement in the impairment losses on trade receivables is as follows:

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
At the beginning of the period / year	**5,975,916**	3,719,548	3,719,548
Charge for the period / year	**1,664,827**	2,535,956	2,690,128
Written off during the period / year	**(16,298)**	(5,806)	(433,760)
Recoveries of amounts previously written off	**--**	6,120	--
	7,624,445	6,255,818	5,975,916

Trade receivables are non-interest bearing and are generally settled on terms of 60 days.

11. FINANCIAL ASSETS MEASURED AT FVTPL

As at 30 September 2026, financial assets at fair value through profit or loss comprise an investment in a money market fund amounting to ﷼354 million (31 December 2025: nil). The investment is held with the intention of trading and disposal within the next 12 months and is measured at fair value based on the net asset value per unit as reported by the fund manager and is classified within Level 2 of the fair value hierarchy.

During the nine-months period ended 30 September 2026, the Group recognized fair value gain of ﷼ 12.5 million (30 September 2025: nil), as presented in the condensed consolidated statement of profit or loss.

12. CASH AND CASH EQUIVALENTS

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Cash at banks	**58,685,643**	35,149,376	450,978,946
Cash on hand	**100,389,834**	112,332,745	103,464,266
Islamic Murabaha deposits*	**--**	489,200,000	--
	159,075,477	636,682,121	554,443,212

* At 30 September 2026, the Group had short-term Islamic Murabaha deposits with original maturities of less than three months. During the period ended 30 September 2026, the Group earned ﷼ 15.4 million (30 September 2025; ﷼ 39.2 million) on the Islamic Murabaha deposits at rate of return ranging between 3.40% to 5.35% as presented under “Finance income” in the condensed consolidated statement of profit or loss.

13. SHAREHOLDERS’ EQUITY

(a) Capital

The Group's capital is divided into 130,000,000 shares as at 30 September 2026 (31 December 2025: 130,000,000 shares) with a nominal value of 10 each (31 December 2025: ﷼ 10 each).

(b) Dividends

- On 28 June 2026 (corresponding 29 Muharram 1448H) the Board of Directors announced the distribution of 338 million as interim cash dividends (﷼ 2.6 per share) which represents 26% of the nominal value of the shares.

- On 8 March 2026 (corresponding 19 Ramadan 1447H) the Board of Directors announced the distribution of ﷼ 390 million as cash dividends (﷼ 3 per share) for the second half of the year 2025 which represents 30% of the nominal value of the shares.

- On 29 July 2025 (corresponding 4 Safar 1447H) the Board of Directors announced the distribution of ﷼338 million as interim cash dividends (﷼ 2.60 per share) which represents 26% of the nominal value of the shares.

13. SHAREHOLDERS' EQUITY (continued)

(b) Dividends (continued)

- On 10 March 2025 (corresponding 10 Ramadan 1446H) the Board of Directors announced the distribution of ﷼ 390 million as cash dividends (﷼ 3 per share) for the second half of the year 2024 which represents 30% of the nominal value of the shares.

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼
Cash dividends for the second half of the year 2025: ﷼ 3.00 per share (second half of the year 2024: ﷼ 3.00 per share)	**390,000,000**	390,000,000
Cash dividends for the first half of the year 2026: ﷼ 2.60 per share (first half of the year 2025: ﷼ 2.60 per share)	**338,000,000**	338,000,000
Total dividends for the period / year	**728,000,000**	728,000,000

(c) Statutory reserve

On 29 April 2025, the General Assembly Meeting of the shareholders approved the transfer of the statutory reserve balance amounting to ﷼ 369,207,440, as reported in the financial statements for the year ended 31 December 2024, to retained earnings.

14. EMPLOYEE BENEFIT LIABILITIES

The Group operates an approved unfunded employees' end of service benefits plan ("EOSB") for its employees as required by the Saudi Arabian Labor Law. The following table represents the movement of the defined benefits obligation:

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
Defined benefits obligation at beginning of the period / year	**421,460,663**	420,490,334	420,490,334
Current service cost	**36,381,808**	41,674,247	53,690,377
Interest cost on defined benefits obligation	**16,002,141**	16,527,004	22,094,987
Total expense charged to statement of profit or loss	**52,383,949**	58,201,251	75,785,364
Actuarial gain on the obligation	**(57,444,884)**	(2,943,076)	(54,511,902)
Transferred out	**(2,307)**	--	--
Payments made during the period / year	**(24,664,063)**	(16,862,982)	(20,303,133)
Defined benefits obligation at the end of the period / year	**391,733,358**	458,885,527	421,460,663

15. ZAKAT AND TAX

The movement in the zakat and tax provision during the period / year is as follows:

	30 September 2026 (Unaudited) ﷼	30 September 2025 (Unaudited) ﷼	31 December 2025 (Audited) ﷼
At the beginning of the period / year	**50,714,818**	76,969,511	76,969,511
Charge for the period / year	**14,551,927**	2,701,917	15,168,821
Release during the period / year	**(3,855,932)**	--	--
Total zakat charge, net	**10,695,995**	2,701,917	15,168,821
Payment during the period / year	**(32,397,369)**	(41,270,994)	(41,423,514)
Refund during the period / year	**3,149,299**	--	--
At the end of the period / year	**32,162,743**	38,400,434	50,714,818

During the year ended 31 December 2023, the Group subsidiaries that are operated in KSA, (the Parent Company, Nahdi Care Company, and Al Sakhaa Golden Trading and Contracting Company) obtained an approval from ZATCA to submit their Zakat based on a unified return. Starting from the year ended 31 December 2023 and onward Zakat returns will be based on the unified return.

Status of assessments

Nahdi Medical Company

For the year ended 31 December 2015
An objection was filed against the Zakat, Tax, and Customs Authority's ("The authority") assessment of zakat differences amounting to ﷼ 6,017,417 via the website of the General Secretariat of Tax Committees within the statutory period. Subsequently, the company paid ﷼ 1,017,417 representing some of the disputed items, on 29 December 2022. The Authority attached a memorandum explaining its desire to drop its appeal on the remaining disputed amount of ﷼ 5,000,000. The Appeals Committee issued a decision accepting the dismissal of the dispute in the appeal filed by the Authority. The Authority's amended assessment was issued, reflecting the committee's decisions and finalizing the zakat status for the year.

For the years ended 31 December 2016 to 2019
A final assessment was issued by the Authority, and the company paid the zakat differences.

For the years ended 31 December 2020 to 2023
The company has submitted its zakat returns for these years and the final assessment has been issued for zakat differences amounting to ﷼ 6,650,697 and the company paid the zakat differences.

For the years ended 31 December 2024 to 2025
The Company submitted zakat return for the year and no zakat assessment was received. The Company received a valid zakat certificate until 30 April 2027.

For the period ended 30 September 2026
The zakat status remains as mentioned above.

15. ZAKAT AND TAX (continued)

Status of assessments (continued)

(Subsidiaries)

Al Sakhaa Golden Trading and Contracting Company

For the years from starting operations till year ended 31 December 2015
The company has filed zakat returns for these years, but no zakat assessments was received.

For the years from the year ended 31 December 2016 till the year ended 31 December 2019
A final assessment has been issued by the ZATCA, and the company has settled the zakat differences. Accordingly, the zakat status for the above years is considered finalized.

For the years ended 31 December 2020 to 2025
The Company submitted zakat return for the year and no zakat assessment was received. The Company received a valid zakat certificate until 30 April 2027.

For the period ended 30 September 2026
The zakat status remains as mentioned above.

Nahdi Care Limited Company

For the years ended 31 December 2019 to 2025
The Company submitted zakat return for the years and no zakat assessment was received. The Company received a valid zakat certificate until 30 April 2027.

For the period ended 30 September 2026
The zakat status remains as mentioned above.

Tax Status

Nahdi Investment CO. L.L.C and the subsidiaries

The Company submitted its tax return for the year 2025 and recorded a nil tax liability.

Al Sakhaa integrated solutions

The Company filed its 2025 corporate income tax return on 30 April 2026, reporting a tax liability of EGP 102,445 (﷼7,704). As of the reporting date, no tax assessment has been received.

16. REVENUE

	Three-month period ended 30 September		Nine-month period ended 30 September	
	2026	2025	**2026**	2025
	﷼	﷼	﷼	﷼
Front Shop (non-pharma)	**1,076,167,515**	1,057,171,264	**3,272,169,846**	3,229,710,990
Pharma	**1,427,860,581**	1,262,654,907	**4,324,222,181**	3,980,513,625
Others*	**187,930,773**	141,630,724	**564,265,500**	413,750,663
	2,691,958,869	2,461,456,895	**8,160,657,527**	7,623,975,278

There is no individual customer contributed more than 10% of the Group's total sales.

The revenue is recognized at a point of time.

* Others mainly include revenue generated from services provided by the clinics under Nahdi Care Limited Company.

17. EARNINGS PER SHARE

The earnings per share calculation is given below:

	Three-month period ended 30 September		Nine-month period ended 30 September	
	2026	2025	**2026**	2025
	﷼	﷼	﷼	﷼
Net profit for the period	**171,772,992**	161,248,856	**622,681,958**	654,815,917
Weighted average number of ordinary shares	**130,000,000**	130,000,000	**130,000,000**	130,000,000
Earnings per share – Basic and diluted	**1.32**	1.24	**4.79**	5.04

There has been no item of dilution affecting the weighted average number of ordinary shares.

18. FAIR VALUE MEASUREMENT

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability; or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group.

18. FAIR VALUE MEASUREMENT (continued)

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All financial instruments for which fair value is recognized or disclosed are categorized within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:

- Level 1: quoted (unadjusted) market prices in active markets for identical assets or liabilities.
- Level 2: valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable.
- Level 3: valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

If the inputs used to measure the fair value of an asset or liability falls into different levels of the fair value hierarchy, then the fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest input level that is significant to the entire measurement.

The Group recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. There were no transfers among the levels during the period.

The management assessed that the fair value of financial assets and financial liabilities approximate their carrying amounts primarily due to the short-term maturities of these instruments.

The fair value of investment properties was determined using the Market Approach, which is classified as a Level 2 fair value measurement where observable market data for comparable properties was available. For properties where such data was limited, the Residual Method was used, which is classified as a Level 3 fair value measurement due to the use of unobservable inputs and significant valuation assumptions.

19. RELATED PARTY TRANSACTIONS AND BALANCES

Related parties represent the shareholders, directors and key management personnel of the Group, affiliates (the Company and the entities are members of the same group), and entities controlled, jointly controlled, or significantly influenced by such parties. Pricing policies and terms of these transactions are approved by the Group’s management.

19. RELATED PARTY TRANSACTIONS AND BALANCES (continued)

Key management compensation

Compensation for key management and Board Directors is as follows:

	Three-month period ended 30 September		Nine-month period ended 30 September	
	2026	2025	**2026**	2025
	﷼	﷼	﷼	﷼
Salaries and other benefits	**875,000**	875,000	**2,625,000**	2,625,000
Post-employment benefits	**(610,633)**	4,235,436	**7,465,570**	8,573,620
	264,367	5,110,436	**10,090,570**	11,198,620

The amounts disclosed in the above table are the amounts recognised as an expense during the period related to key management personnel.

20. SEGMENT INFORMATION

The Group operates mainly in the KSA and the UAE and is engaged in retail trading as sale of cosmetics, medical materials, as well as medical equipment through pharmacies. It also operates specialized medical clinics through one of its subsidiaries. The Group's operations in the UAE are considered relatively insignificant, and accordingly, the Group does not present business sector information at the geographical level as at present more than 90% of the Group's operations are conducted within the Kingdom of Saudi Arabia. Also, the Group's business of operating specialized medical clinics is considered relatively insignificant. the management has concluded that except for retail trading of consumer goods all other lines of businesses are less than 10% of combined revenue, profit or loss and assets of the Group. The Group has considered the overriding core principles of IFRS 8 'Operating segments' as well as its internal reporting framework, management and operating structure. The Directors' conclusion is that the Group has one operating segment, that of retailing

Key internal reports received by the CODM, primarily the selling and operation plan (SOP), focus on the performance of the Group as a whole. The operations of all elements of the business are driven by the retail sales environment and hence have fundamentally the same economic characteristics. All operational decisions made are focused on the performance and growth of the retail outlet.

21. COMMITMENTS AND CONTINGENCIES

As at 30 September 2026, the Group has commitments of ﷼40.29 million (31 December 2025: ﷼ 111 million) relating to capital expenditures, which also includes an agreement with a consulting Group to implement the decorations of pharmacies, implement the new stores, construction of distribution centre. It also includes commitments pertains to letter of credit, letter of guarantee and commitment towards lessors.

22. EVENTS DURING AND AFTER REPORTING PERIOD

During the period ended **30 September 2026**, and up to the date of approval of the financial statements for issuance on 27 October 2026, the Middle East region witnessed rapid geopolitical and security developments that led to an increased level of instability in some regional markets. These developments may have potential impacts on the Company's operations in the coming period, including risks related to the continuity of supply chains, delays in some operational activities, or an increase in some operational or logistical costs. Management believes that this has no significant impact on the Company's operations and its ability to continue as going concern entity. The Management is closely monitoring the situation and regularly updating its assessments of risks and potential impacts.

23. APPROVAL OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

These condensed consolidated interim financial statements were approved by the Board of Directors on 27 October 2026, corresponding to 16 Jumada Al Awal 1448H.